AgomAb Therapeutics (AGMB) Insider buying
10 open-market purchases of AGMB by AgomAb Therapeutics's executives and directors since October 2026, worth $389,520 in total, from SEC Form 4 filings.
Summary
The most recent: David R Epstein, Director bought $34,050 on November 5, 2026.
The biggest buyer over the period is David R Epstein (Director): 5 purchases, $209,200.
By year
| Year | Purchases | Value |
|---|---|---|
| 2026 | 10 | $389,520 |
Biggest buyers
| Insider | Buys | Value |
|---|---|---|
| David R Epstein Director | 5 | $209,200 |
| Tim Jasper Knotnerus Chief Executive Officer | 2 | $94,380 |
| Pierre Thadee Victor Kemula Chief Financial Officer | 3 | $85,940 |
Every purchase
Newest first. From SEC Form 4 filings. Insider buying across the market.
| Date | Insider | Shares | Price | Value | Filing |
|---|---|---|---|---|---|
| Nov 5, 2026 | R Epstein David Director |
5,000 | $6.81 | $34,050 | Form 4 |
| Oct 21, 2026 | R Epstein David Director |
5,000 | $8.86 | $44,300 | Form 4 |
| Oct 8, 2026 | R Epstein David Director |
5,000 | $8.90 | $44,500 | Form 4 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer |
5,000 | $8.57 | $42,850 | Form 4 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer |
2,000 | $8.54 | $17,080 | Form 4 |
| Oct 6, 2026 | R Epstein David Director |
5,000 | $8.70 | $43,500 | Form 4 |
| Oct 6, 2026 | Jasper Knotnerus Tim Chief Executive Officer |
5,000 | $8.70 | $43,500 | Form 4 |
| Oct 6, 2026 | Thadee Victor Kemula Pierre Chief Financial Officer |
3,000 | $8.67 | $26,010 | Form 4 |
| Oct 5, 2026 | Jasper Knotnerus Tim Chief Executive Officer |
6,000 | $8.48 | $50,880 | Form 4 |
| Oct 5, 2026 | R Epstein David Director |
5,000 | $8.57 | $42,850 | Form 4 |
Questions about AgomAb Therapeutics
Are AgomAb Therapeutics insiders buying the stock?
10 open-market purchases of AGMB by AgomAb Therapeutics's executives and directors since October 2026, worth $389,520 in total, from SEC Form 4 filings. The most recent: David R Epstein, Director bought $34,050 on November 5, 2026.
What counts as insider buying here?
Open-market purchases (Form 4 code P) by officers and directors. Option exercises, grants and purchases by 10% owners are left out.
From AgomAb Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.